Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline
Executive Summary
Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.